VANCOUVER, June 26 /CNW/ - iCo Therapeutics Inc. (TSX-V: ICO) is pleased
to provide further preclinical results supporting the accelerated development
of iCo-009, the company's oral reformulation of Amphotericin B (Amp B). Amp B
is a generic drug that has been in use for approximately 50 years, however its
use is limited as it is currently administered intravenously and has
significant infusion related side effects and kidney toxicity.
